Takeda to acquire exclusive worldwide (ex-china) license of hutchmed's fruquintinib, a highly selective, oral vegfr1/2/3 tyrosine kinase inhibitor

Osaka, japan & cambridge, mass.--( business wire )--takeda (tse:4502/nyse:tak) today announced that it has entered into an exclusive licensing agreement with hutchmed (china) limited (nasdaq/aim: hcm, hkex: 13) and its subsidiary hutchmed limited, for the further development and commercialization of fruquintinib outside of mainland china, hong kong and macau.
TAK Ratings Summary
TAK Quant Ranking